Related Experiment Video
Updated: Jul 7, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Stroke Prevention in Atrial Fibrillation: Our Current Failures and Required Research
M Edip Gurol1, Clinton B Wright2, Scott Janis
1Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.G., E.G.).
Insights
For patients with atrial fibrillation, new research explores reducing stroke and bleeding risks. Current treatments like anticoagulants and left atrial appendage closure have limitations, prompting investigation into novel therapies.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Nonvalvular atrial fibrillation (AF) is a prevalent condition associated with increased risk of ischemic strokes and systemic embolism.
- Current oral anticoagulants effectively reduce ischemic events but elevate bleeding risks and require strict adherence.
- Existing treatments like left atrial appendage closure offer non-pharmacological stroke prevention but carry procedural risks.
Purpose of the Study:
- To review current stroke prevention strategies for atrial fibrillation (AF).
- To identify research gaps and future directions for minimizing ischemic and hemorrhagic risks in AF patients.
- To discuss the benefits, risks, and limitations of existing and emerging AF therapies.
Main Methods:
- Consensus statement from a workshop involving academia and industry experts.
- Review of FDA-approved treatments including direct thrombin inhibitors, factor Xa inhibitors, and left atrial appendage closure.
- Discussion of ongoing research, particularly phase 3 trials for factor XIa inhibitors.
Main Results:
- Established treatments have trade-offs between efficacy and safety (e.g., anticoagulants vs. bleeding).
- Left atrial appendage closure presents an alternative but has potential complications.
- Emerging therapies like factor XIa inhibitors are under investigation for improved risk profiles.
Conclusions:
- Further research is crucial to optimize stroke prevention in AF, balancing ischemic and bleeding risks.
- High-risk patient populations require tailored therapeutic approaches.
- A comprehensive understanding of novel agents and interventions is needed for improved patient outcomes.
Abstract:
Nonvalvular atrial fibrillation is a common rhythm disorder of middle-aged to older adults that can cause ischemic strokes and systemic embolism. Lifelong use of oral anticoagulants reduces the risk of these ischemic events but increases the risk of major and clinically relevant hemorrhages. These medications also require strict compliance for efficacy, and they have nontrivial failure rates in higher-risk patients. Left atrial appendage closure is a nonpharmacological method to prevent ischemic strokes in atrial fibrillation without the need for lifelong anticoagulant use, but this procedure has the potential for complications and residual embolic events. This workshop of the Roundtable of Academia and Industry for Stroke Prevention discussed future research needed to further decrease the ischemic and hemorrhagic risks among patients with atrial fibrillation. A direct thrombin inhibitor, factor Xa inhibitors, and left atrial appendage closure are FDA-approved approaches whereas factor XIa inhibitors are currently being studied in phase 3 randomized controlled trials for stroke prevention. The benefits, risks, and shortcomings of these treatments and future research required in different high-risk patient populations are reviewed in this consensus statement.
More Related Videos
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
08:00Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter
Published on: June 15, 2015
